Ironwood Pharmaceutical a Aktie

Ironwood Pharmaceutical a für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A0X789 / ISIN: US46333X1081

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
25.04.2025 13:22:36

Ironwood Raises 2025 Adj. EBITDA Outlook

(RTTNews) - Ironwood Pharmaceuticals (IRWD) reiterated full year 2025 LINZESS U.S. net sales and total Ironwood revenue guidance and increased adjusted EBITDA guidance. The company has raised full-year 2025 adjusted EBITDA guidance to greater than $105 million as it no longer plans to make certain apraglutide commercial launch planning investments and will shift focus to the confirmatory Phase 3 trial. Previously, the company projected adjusted EBITDA to be greater than $85 million.

"In the first quarter of 2025, we saw continued strong prescription demand growth of 8% year-over-year, which was offset by anticipated pricing headwinds as well as a change in estimate of AbbVie gross-to-net rebate reserves, which was refined to reflect rebates owed for units dispensed in the first quarter of 2025. We do not expect first quarter LINZESS U.S. net sales results or this change in estimate to impact the full-year results," said Tom McCourt, CEO of Ironwood.

Ironwood plans to report full first quarter results in early May.

Nachrichten zu Ironwood Pharmaceuticals Inc (A)mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Ironwood Pharmaceuticals Inc (A)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Ironwood Pharmaceuticals Inc (A) 1,25 -4,58% Ironwood Pharmaceuticals Inc (A)